VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF PRUSOGLIPTIN TABLETS

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. (Incorpor ated in H ong Kong with limi ted liabi lity) (Stock co de: 1093) VOLUNTARY ANNOUNCEMENT NMPA ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF PRUSOGLIPTIN TABLETS The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the application for marketing approval of Class 1 new drug Prusogliptin Tablets (the “Product”) developed by CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.* (石藥集團中奇製藥技術 （石家莊） 有限公司), a subsidiary of the Company, for the treatment of type 2 diabetes has been accepted by the National Medical Products Administration (NMPA) of the People’s Republic of China. Prusogliptin tablet is a new oral dipeptidyl peptidase-IV (DPP-4) inhibitor which is highly selective and strongly inhibitory towards DPP-4. Through the inhibition of DPP-4, the level of endogenous active glucagon-like peptide-1 (GLP-1) is elevated and the sensitivity of β cells and α cells towards glucose is enhanced, leading to increased glucose stimulated insulin release and enhanced inhibitory effect of glucose towards glucagon secretion, thereby decreasing blood glucose level without inducing hypoglycemia and weight gain. Clinical studies demonstrated that the Product has long-lasting hypoglycemic effect with a low incidence of adverse reactions, providing more option for the treatment of patients with type 2 diabetes. By Order of the Board CSPC Pharmaceutical Group Limited CAI Dongchen Chairman Hong Kong, 26 April 2023 As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors. * For identification purposes only

The release as fetched from its publisher. irasia.com ↗